Trials / Completed
CompletedNCT01936909
Interleukin-1 Blockade in Recently Decompensated Heart Failure
Interleukin-1 Blockade in Recently Decompensated Heart Failure: A Randomized Placebo-controlled Double-blinded Study
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Virginia Commonwealth University · Academic / Other
- Sex
- All
- Age
- 21 Years – 130 Years
- Healthy volunteers
- Not accepted
Summary
The RED-HART is a randomized double-blinded placebo-controlled study of Anakinra (IL-1 blocker) in patients with recently decompensated heart failure to determine the safety and efficacy in terms of aerobic exercise capacity and ventilatory efficiency measured with a cardiopulmonary exercise test.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anakinra (weeks 1-2) | Anakinra 100 mg daily for weeks 1 and 2 |
| DRUG | Anakinra (weeks 3-12) | |
| DRUG | Placebo |
Timeline
- Start date
- 2014-02-01
- Primary completion
- 2016-09-23
- Completion
- 2016-09-23
- First posted
- 2013-09-06
- Last updated
- 2017-12-22
- Results posted
- 2017-12-22
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01936909. Inclusion in this directory is not an endorsement.